Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Eascra Biotech Appoints Dr. Andrew Goodearl As Chief Scientific Officer

PRIVATEAug 27, 2026•about 3 hours ago

Position

Chief Scientific Officer

Company

Eascra Biotech

Dr. Andrew Goodearl
WorcesterBiotechnologyHealth CareTherapeutics

Description

Eascra Biotech has appointed Dr. Andrew Goodearl, Ph.D., as Chief Scientific Officer. Dr

Company Information

Company

Eascra Biotech

Location

Worcester, Massachusetts, United States

About

Eascra Biotech is an early-stage nanomedicine startup providing an advanced therapeutic delivery platform capable of delivering RNA, gene editing, and other therapeutics to hard-to-reach treatment sites, such as articular cartilage, kidneys, and solid tumors. Its mission is to advance this technology for the benefit of patients worldwide. Eascra's proprietary delivery mechanism, a Janus Base Nanoparticle (JBNp) invented by Eascra co-founder Dr. Yupeng Chen, mimics DNA and is customizable for different treatment indications.

Don't miss Eascra Biotech's next move

Get an email the moment Eascra Biotech changes its leadership, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for Eascra Biotech's next move

Learn about Strategic plan

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months

Eascra Biotech changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.